. 2018 Oct 16;11:89. doi: 10.1186/s13048-018-0463-3

Table 2.

Metabolic inhibitors sensitize SKOV3 cultures to cytotoxicity via TRAIL or cisplatin

A		TRAIL
A		Untreated	50 ng/mL	100 ng/mL	ANOVA
FCCP (μM)	Vehicle	1.00 ± 0.02^a	0.90 ± 0.06^a	0.93 ± 0.02^a	0.1901
	1.0	0.98 ± 0.04^a	0.85 ± 0.04^a*	0.90 ± 0.02^a	0.0448
	2.5	0.94 ± 0.03^a	0.75 ± 0.04^a**	0.79 ± 0.01^b**	0.0011
	5.0	0.91 ± 0.02^a	0.69 ± 0.03^b**	0.72 ± 0.02^b**	7.16E-05
ANOVA		0.1335	0.0143	1.28E-06
B		Cisplatin
B		Untreated	1 μM	10 μM	ANOVA
FCCP (μM)	Vehicle	1.00 ± 0.01^a	0.95 ± 0.07^a	1.07 ± 0.04^a	0.2609
	1.0	0.96 ± 0.04^a,b	0.85 ± 0.03^a	0.99 ± 0.04^a	0.1036
	2.5	0.85 ± 0.00^b,c	0.91 ± 0.05^a	0.95 ± 0.04^a	0.2008
	5.0	0.80 ± 0.02^c	0.78 ± 0.04^a	0.88 ± 0.02^b	0.1185
ANOVA		0.0012	0.1549	0.0384
C		TRAIL
C		Untreated	50 ng/mL	100 ng/mL	ANOVA
Oligomycin (μM)	Vehicle	1.0 ± 0.04^a	0.97 ± 0.04^a	0.95 ± 0.02^a	0.5931
	1.0	0.90 ± 0.01^a	0.85 ± 0.01^a	0.80 ± 0.01^b**	0.006
	2.5	0.96 ± 0.04^a	0.82 ± 0.05^a	0.81 ± 0.00^b	0.0483
	5.0	0.86 ± 0.03^a	0.82 ± 0.08^a	0.84 ± 0.04^b	0.9093
ANOVA		0.0507	0.2121	0.0062
Cisplatin
		Untreated	1 μM	10 μM	ANOVA
Oligomycin (μM)	Vehicle	1.00 ± 0.03^a	0.88 ± 0.09^a	0.94 ± 0.02^a	0.3459
	1.0	0.92 ± 0.02^a	0.85 ± 0.01^a*	0.84 ± 0.01^b*	0.0129
	2.5	0.91 ± 0.02^b	0.84 ± 0.03^a	0.89 ± 0.01^a	0.1578
	5.0	0.91 ± 0.00^b	0.88 ± 0.03^a	0.84 ± 0.03^b	0.2232
ANOVA		0.0279	0.9114	0.0135

Resistance of SKOV3 cultures to cell death inducing agents TRAIL or cisplatin was analyzed through inhibition of OXPHOS using oligomycin A and a mitochondrial membrane potential uncoupler, FCCP, using MTS viability assays. Results are presented as fold change to vehicle treated control cultures with differing letters indicating significant (p < 0.05) changes in viability with treatment of inhibitor, and asterisks indicating significant (* p < 0.05; ** p < 0.01) changes in viability with treatment of cytotoxic agent (A) Pretreatment with FCCP sensitized SKOV3 cultures to TRAIL, (B) but not cisplatin. (C) Culture viability was decreased with oligomycin A treatment prior to TRAIL, (D) as well as cisplatin